Verrica Pharmaceuticals (VRCA) Cash from Financing Activities (2017 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Cash from Financing Activities of -$120000.0 for Q1 2026, up 97.04% year-over-year from -$60900.7 in Q1 2025, and down 100.88% quarter-over-quarter from $13.6 million in Q4 2025.
Verrica Pharmaceuticals (VRCA) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at -$120000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 97.04% year-over-year to -$120000.0; the TTM figure through Mar 2026 stood at $5.4 million (down 84.32% YoY), while the FY2025 annual figure was $1.4 million, down 96.17% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$120000.0, down from $13.6 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $44.0 million in Q3 2023, with the low at -$16.9 million in Q3 2022.
- The 5-year median for Cash from Financing Activities is -$102000.0 (2023), against an average of $6.0 million.
- The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities sank 39288.37% in 2022, then soared 168322.22% in 2023.
- Verrica Pharmaceuticals' Cash from Financing Activities stood at -$16.9 million in 2022, then surged by 99.84% to -$27000.0 in 2023, then jumped by 146122.22% to $39.4 million in 2024, then plunged by 65.4% to $13.6 million in 2025, then tumbled by 100.88% to -$120000.0 in 2026.
- Business Quant data shows VRCA's Cash from Financing Activities at -$120000.0 in Q1 2026, $13.6 million in Q4 2025, and -$4.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Verrica Pharmaceuticals | 102.80 Mn | 91.60 Mn | - | -126,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -126,000.00 |
| Jun 30, 2026 | -126,000.00 |
| Mar 31, 2026 | -120,000.00 |
| Mar 31, 2026 | -120,000.00 |
| Dec 31, 2025 | 13.64 Mn |
| Dec 31, 2025 | 13.64 Mn |
| Sep 30, 2025 | -3.98 Mn |
| Sep 30, 2025 | -3.98 Mn |
| Jun 30, 2025 | -4.16 Mn |
| Jun 30, 2025 | -4.16 Mn |
| Mar 31, 2025 | -4.06 Mn |
| Mar 31, 2025 | -4.06 Mn |
| Dec 31, 2024 | 39.43 Mn |
| Dec 31, 2024 | 39.43 Mn |
| Sep 30, 2024 | -397,000.00 |
| Sep 30, 2024 | -397,000.00 |
| Jun 30, 2024 | -640,000.00 |
| Jun 30, 2024 | -640,000.00 |
| Mar 31, 2024 | -661,000.00 |
| Mar 31, 2024 | -661,000.00 |